Status In progress
Process STA pre-2018
ID number 974

Provisional Schedule

Expected publication 24 October 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Janssen
Others Department of Health and Social Care
  NHS England
  NHS Bradford Districts CCG
  NHS Heywood, Middleton and Rochdale CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Association
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Health Forum
  UK Myeloma Forum
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Amgen (carfilzomib)
  Celgene (lenalidomide and pomalidomide)
  Concordia International (dexamethasone)
  Dr Reddy’s Laboratories (bendamustine)
  Janssen (bortezomib, daratumumab and doxorubicin)
  Medac UK (bendamustine, doxorubicin)
  Napp Pharmaceuticals (bendamustine)
  Novartis (panobinostat)
  Zentiva (bendamustine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bloodwise
  Cochrane Haematological Malignancies Group
  Institute of Cancer Research
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
03 January 2018 Invitation to participate
02 August 2016 - 31 August 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
08 June 2016 Referral
08 June 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance